Try Alerts Free   |   Login
Health Care › Services-Commercial Physical And Biological Research

SRNE Price Correlated With Financials For Sorrento Therapeutics

Free historical financial statements for Sorrento Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with SRNE stock chart to see long term trends.

SRNE Stock Compared to Quarterly

SRNE Income Statement

Revenue, Net:11461000
Revenue Per Share:0.0255
Selling, General & Admin Expense:48136000
Research & Development Expense:48467000
Total Operating Expenses:129822000
Operating Income:-220599000
Income Taxes:-1050000
Net Income:-219477000
Earnings Per Share, Basic:-0.54
Shares Outstanding, Basic Avg:449952163

SRNE Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:3675000
Net Cash from Operations:-92211000
Net Cash from Operations Per Share:-0.2049
Net Cash from Financing Activities:144283000
Property, Plant & Equipment Purchases:3089000
Net Cash from Investing Activities:-13187000
Net Change in Cash & Equivalents:38885000

SRNE Balance Sheet

Cash and Cash Equivalents:70345000
Short-Term Investments:63259000
Accounts Receivable, Net:24715000
Inventories:20697000
Total Current Assets:196048000
Property, Plant & Equipment, Net:42530000
Total Assets:632132000
Accounts Payable:24937000
Current Portion of Long-Term Debt:23714000
Total Short-Term Liabilities:145321000
Long Term Debt, Non-Current Portion:83069000
Total Liabilities:496369000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Ji Henry   President, CEO and Chairman of the Board of Directors
88,888 sh at $2
$179,349
Buy
Ji Henry   President, CEO and Chairman of the Board of Directors
55,555 sh at $2
$108,882
Buy
Ji Henry   President, CEO and Chairman of the Board of Directors
33,333 sh at $2
$70,333
Buy
Ji Henry   President, CEO and Chairman of the Board of Directors
22,222 sh at $2
$45,768
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
State Street Corp
39,661,099 sh
5,700,215 sh
17%
$79,719
$590
Blackrock Inc.
33,950,557 sh
11,915,668 sh
54%
$68,242
$16,901
Vanguard Group Inc
20,896,424 sh
4,995,039 sh
31%
$42,002
$4,951
Geode Capital Management, LLC
6,892,947 sh
1,906,514 sh
38%
$13,854
$2,236
D. E. Shaw & Co., Inc.
5,881,402 sh
-1,360,489 sh
-19%
$11,822
-$5,052
JPMorgan Chase & Co
3,269,037 sh
-29,062 sh
-1%
$6,571
-$1,112
Morgan Stanley
2,972,031 sh
-309,183 sh
-9%
$5,972
-$1,673
Charles Schwab Investment Management Inc
2,766,904 sh
565,217 sh
26%
$5,562
$432
Susquehanna International Group, Llp
2,127,240 sh
1,022,040 sh
92%
$4,276
$1,701
Goldman Sachs Group Inc
1,939,979 sh
362,913 sh
23%
$3,900
$225
Citigroup Inc
1,780,555 sh
1,341,465 sh
306%
$3,579
$2,556
Rafferty Asset Management, LLC
1,751,066 sh
-719,616 sh
-29%
$3,520
-$2,237
Nuveen Asset Management, LLC
1,547,181 sh
522,509 sh
51%
$3,110
$538
Bank Of America Corp /De/
1,388,992 sh
1,388,992 sh
NEW
$2,791
$2,791
Mirae Asset Global Investments Co., Ltd.
1,335,071 sh
429,224 sh
47%
$2,683
$572
Susquehanna International Group, Llp
Call options for 1,270,600 sh
1,270,600 sh
NEW
$2,554
$2,554
Bank Of New York Mellon Corp
1,209,139 sh
223,637 sh
23%
$2,430
$133
UBS Group Ag
1,135,069 sh
-1,345,692 sh
-54%
$2,281
-$3,499
Susquehanna International Group, Llp
Put options for 1,131,200 sh
1,131,200 sh
NEW
$2,274
$2,274
Cubist Systematic Strategies, LLC
829,079 sh
592,679 sh
251%
$1,666
$1,115

Data imported from Sorrento Therapeutics Inc SEC filings. Check original filings before making any investment decision.